Get notified when CRGT files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The company's financial statements and auditor's report include substantial doubt about its ability to continue as a going concern.
  • Controlled Company (new) — Cortigent will be a controlled company under NYSE rules, allowing it to rely on exemptions from independent director and committee requirements.
  • Related-party Debt (new) — The company owes Vivani $1.5 million from offering proceeds plus a $2 million promissory note at 5% interest due in five years.
  • Sole-source Suppliers (new) — Cortigent relies on a limited number of sole-source suppliers for critical manufacturing steps, increasing supply chain risk.
  • Co-owned Patents Without Agreements (new) — The company co-owns seven patents with third parties but lacks agreements on commercialization and enforcement, weakening its IP position.
  • No Product Liability Insurance (new) — Cortigent currently maintains no product liability insurance, exposing it to potential uninsured losses from product liability claims.
CRGT CRGT S-1/A

Cortigent (CRGT) files S-1/A for $15M IPO at $10/share; pre-revenue neurostimulation developer with going-concern doubt

Filed May 13, 2026 · ~2 min read

Key Changes

  • high

    Cortigent, a wholly owned subsidiary of Vivani Medical, plans to sell 1.5M shares at $10.00 each, raising $15M gross; net proceeds to the company are estimated at $13.4M.

    The Offering verify on EDGAR →
  • high

    The company is pre-revenue with no commercial products; it reported a GAAP net loss of $3.8M for the most recent period and has an accumulated deficit of $11.6M.

    Management's Discussion and Analysis verify on EDGAR →
  • high

    Use of proceeds: $3M for R&D, $1M for Orion pivotal trial, $4M for manufacturing, $1.5M to repay Vivani, and the remainder for working capital; additional funding will be needed to complete trials.

    Use of Proceeds verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.

Partner

Trade CRGT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify